I. AMENDMENTS

In the claims:

1-23 (Canceled)

24. (New) A method of treating a B cell lymphoma in a mammal, comprising administering a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody that binds CD20, the antibody not subjected to prior lyophilization, an acetate buffer from about pH 4.8 to about 5.5, a surfactant and a polyol, wherein the formulation lacks a tonicifying amount of sodium chloride.

25. (New) The method of claim 24 wherein the formulation is isotonic.

26. (New) The method of claim 24 wherein the formulation is stable at a temperature of about 2-8°C for at least one year.

27. (New) The method of claim 24 wherein the formulation is stable at a temperature of about 2-8°C for at least two years.

28. (New) The method of claim 24 wherein the formulation is stable at about 30°C for at least one month

29. (New) The method of claim 24 wherein the formulation is stable following freezing and thawing of the formulation.

30. (New) The method of claim 24 wherein the polyol is a nonreducing sugar.

31. (New) The method of claim 30 wherein the nonreducing sugar is trehalose.

32. (New) The method of claim 30 wherein the nonreducing sugar is sucrose.

33. (New) The method of claim 24 wherein the antibody is an antibody fragment.

34. (New) The method of claim 33 wherein the antibody fragment is a $F(ab')_2$.

35. (New) The method of claim 24 wherein the antibody concentration in the formulation is from about 0.1 to about 50 mg/mL.

36. (New) The method of claim 35 wherein the antibody is present in an amount of about 30-50 mg/mL.

37. (New) The method of claim 24 wherein the surfactant is a polysorbate.

38. (New) The method of claim 24 wherein the acetate is present in an amount of about 5-30 mM.

39. (New) The method of claim 38 wherein the acetate is present in an amount of 10-30 mM.

40. (New) The method of claim 24 wherein the formulation further comprises a preservative.

41. (New) The method of claim 40 wherein the preservative is benzyl alcohol.

42. (New) The method of claim 24, wherein the acetate buffer is at pH 5.0.

43. (New) The method of claim 24 wherein the buffer is 10-30 mM sodium acetate at pH 5, the polyol is trehalose in an amount of about 2-10% w/v, the surfactant is polysorbate in an amount of about 0.01-0.1% v/v, wherein the formulation further comprises benzyl alcohol as a preservative and wherein the formulation is stable at a temperature of about 2-8°C for at least two years.

44. (New) A method of treating a hemorrhagic shock in a mammal, comprising administering a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody that binds CD18, the antibody not subjected to prior lyophilization, an acetate buffer from about pH 4.8 to about 5.5, a surfactant and a polyol, wherein the formulation lacks a tonicifying amount of sodium chloride.